10-Q: Kodiak Sciences Faces Going Concern Doubt Amid Losses

Kodiak Sciences reported increased net losses and substantial doubt about its ability to continue as a going concern, despite ongoing progress in its late-stage retinal disease clinical programs.

Summary

• Kodiak Sciences Inc. reported a net loss of $111.8 million for the six months ended June 30, 2025, an increase from $88.2 million for the same period in 2024.
• The company had cash and cash equivalents of $104.2 million as of June 30, 2025, down from $168.1 million at December 31, 2024.
• Accumulated deficit reached $1,440.5 million as of June 30, 2025.
• Management expressed substantial doubt regarding the company's ability to continue as a going concern, stating existing cash may not be sufficient for the next 12 months.
• Research and development expenses increased to $86.4 million for the six months ended June 30, 2025, up from $62.4 million in the prior year, driven by ongoing clinical trials and manufacturing activities.
• General and administrative expenses decreased to $28.2 million for the six months ended June 30, 2025, from $31.6 million in the prior year, partly due to lower stock compensation and reduced net rent expense from a sublease.
• The lead investigational medicine, tarcocimab, is in Phase 3 GLOW2 (diabetic retinopathy, enrollment completed) and DAYBREAK (wet AMD, actively enrolling) clinical trials.
• Topline data for GLOW2 is anticipated in Q1 2026, and for DAYBREAK in Q3 2026.
• Kodiak plans to file a single Biologics License Application (BLA) for tarcocimab in wet AMD, DR, and RVO in 2026, following DAYBREAK topline data.
• KSI-501, an anti-IL-6, VEGF-trap bispecific therapy, is actively enrolling patients in the Phase 3 DAYBREAK study for wet AMD, with topline data expected in Q3 2026.
• KSI-101, a bispecific protein targeting IL-6 and VEGF for macular edema secondary to inflammation (MESI), completed Phase 1b APEX study enrollment, and Phase 3 PEAK and PINNACLE studies are actively enrolling MESI subjects.
• Pipeline programs KSI-102 and KSI-103 are progressing through pre-IND activities, targeting ocular inflammation.
• The ABCD Platform is advancing with duet programs for glaucoma and geographic atrophy towards IND.
• The VETi (Visual Engagement Technology and imager) program, an AIand machine-learning-enabled wearable headset, has achieved significant advancements in hardware, software, and algorithms.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the explicit 'going concern' warning, significant and increasing net losses, and the stated insufficiency of current cash for the next 12 months. While clinical programs are progressing, the severe financial instability overshadows these developments from an investment perspective.

Positives

• Advancement of three late-stage clinical programs (tarcocimab, KSI-501, KSI-101) with active enrollment in Phase 3 studies.
• Completion of enrollment for Phase 3 GLOW2 study for diabetic retinopathy and Phase 1b APEX study for KSI-101.
• Anticipated topline data for GLOW2 in Q1 2026 and for DAYBREAK (tarcocimab and KSI-501) in Q3 2026, providing clear milestones.
• Strategic plan to file a single BLA for tarcocimab across multiple indications (wet AMD, DR, RVO) in 2026.
• Progress in pipeline programs (KSI-102, KSI-103, ABCD Platform for glaucoma and geographic atrophy) towards IND.
• Significant advancements in the VETi digital health program, indicating innovation beyond core drug development.
• Dedicated commercial-scale drug substance manufacturing facility in collaboration with Lonza, potentially positioning the company for market share capture if products are approved.
• Net cash used in operating activities decreased slightly to $63.8 million for the six months ended June 30, 2025, compared to $66.1 million in the prior year.

Negatives

• Substantial doubt regarding the company's ability to continue as a going concern.
• Cash and cash equivalents decreased significantly to $104.2 million as of June 30, 2025, from $168.1 million at December 31, 2024.
• Net losses increased to $111.8 million for the six months ended June 30, 2025, compared to $88.2 million for the same period in 2024.
• Accumulated deficit has grown to $1,440.5 million.
• Existing cash and cash equivalents may not be sufficient to meet anticipated operating and capital expenditure requirements for the next 12 months.
• Prior Phase 3 studies (GLEAM and GLIMMER) for tarcocimab did not meet primary efficacy endpoints, leading to a pause in development and raising concerns about future trial outcomes.
• The company has never generated any revenue from product sales and does not anticipate doing so for several years, if at all.

Risks

• The company is in the clinical stage of drug development with a very limited operating history and no products approved for commercial sale, making future success and viability difficult to evaluate.
• Significant net losses have been incurred since inception, and substantial and increasing net losses are anticipated for the foreseeable future.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• Failure to obtain additional financing may prevent the completion of development and commercialization of product candidates.
• Drug development is highly uncertain and involves substantial risk; there is no assurance of generating revenue or profitability.
• Prospects are heavily dependent on tarcocimab, KSI-501, and KSI-101 product candidates, and their failure could impact the entire ABC Platform.
• Research and development of biopharmaceutical products is inherently risky, with no assurance of regulatory approval.
• Limited resources necessitate prioritization of development, potentially leading to missed opportunities or expenditure on unsuccessful candidates.
• Substantial delays in clinical trials may occur, or trials may not be completed on expected timelines, if at all.
• Clinical trials may fail to demonstrate substantial evidence of durability, efficacy, and safety, preventing or limiting regulatory approval and commercialization.
• Significant competition exists in an environment of rapid technological and scientific change, with competitors potentially retaining market share or developing superior therapies.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable; failure to obtain approval will substantially harm the business.
• Reliance on third parties for clinical trials, research, preclinical testing, and manufacturing carries risks of unsatisfactory performance or supply disruptions.
• Inability to obtain and maintain patent protection for product candidates or the ABC Platform could allow competitors to commercialize similar products.
• High dependence on key personnel; failure to attract, motivate, and retain qualified personnel could hinder business strategy implementation.
• Difficulties in managing organizational growth may arise as the company expands.
• Compromised information technology systems or data could lead to adverse consequences, including regulatory actions, fines, and business disruptions.
• Business disruptions (e.g., earthquakes, power shortages, epidemics, geopolitical conflicts) could harm future revenue and increase costs.
• Economic, political, regulatory, and other risks are associated with international operations, including tariffs and trade barriers.
• The ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes or tax law changes.
• Changes in tax laws or regulations could adversely affect the business.
• Foreign currency exchange rate fluctuations may impact financial position and results.
• Failure to maintain an effective system of internal control over financial reporting could result in material misstatements.
• The market price of common stock may be volatile, leading to substantial losses for investors.
• Future sales of common stock in the public market could cause share price decline.
• Lack of research or negative reports from securities analysts could cause stock price decline.
• Raising additional capital may cause dilution, restrict operations, or require relinquishing rights to technologies.
• Principal stockholders own a significant percentage of common stock, potentially limiting other stockholders' ability to affect key transactions.
• Delaware law and company bylaws might discourage, delay, or prevent a change in control.
• Exclusive forum provisions in bylaws could limit stockholders' ability to obtain a favorable judicial forum for disputes.

Future Outlook

The company expects to continue incurring significant and increasing net losses for the foreseeable future, anticipating that existing cash and cash equivalents may not be sufficient to meet operating and capital expenditure requirements for the next 12 months. It plans to raise additional capital through equity or debt financings, collaborations, or similar transactions. The company aims to file a single Biologics License Application (BLA) for tarcocimab in wet AMD, DR, and RVO in 2026, following topline data from the DAYBREAK study expected in Q3 2026. Topline data for the GLOW2 study is expected in Q1 2026. The company continues to advance its pipeline programs and digital health platform.

Management Comments

• We are a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics.
• Our ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine.
• We believe that the existing cash and cash equivalents may not be sufficient to meet the anticipated operating and capital expenditure requirements for the 12 months following the date of this Quarterly Report on Form 10-Q.
• We continue to monitor and reduce certain expenditures and plans to raise additional capital through approaches that include equity or debt financings, collaborations or a combination of similar transactions.
• We believe these manufacturing capabilities could position us well for potential market share capture if tarcocimab and KSI-501 are approved.
• Kodiak anticipates to be in a position to announce topline data for the primary endpoint for GLOW2 in 1Q 2026 and for the primary endpoint for DAYBREAK in 3Q 2026.
• Kodiak plans to wait for DAYBREAK topline data expected 3Q 2026 in order to file a single Biologics License Application (BLA) for tarcocimab in wet AMD, DR and RVO.
• Kodiak's leadership at the intersection of retinal biology, optics and artificial intelligence continues to advance.

Industry Context

Kodiak Sciences operates in the highly competitive and rapidly evolving biotechnology and pharmaceutical industries, specifically focusing on retinal diseases. The market for retinal therapies is dominated by major pharmaceutical companies like Roche, Regeneron, and Novartis, which have well-established products (e.g., Vabysmo, Eylea HD) and significantly greater financial resources. Kodiak's strategy involves developing next-generation therapies using its ABC Platform and bispecific approaches to address unmet needs like extended durability and targeting disease biology beyond VEGF. The industry is also facing increasing scrutiny over drug pricing and evolving regulatory landscapes, including the impact of the Inflation Reduction Act and potential changes from new tax laws, which could affect market access and profitability for new drugs.

Comparison to Industry Standards

• The company's financial position, characterized by significant net losses and a going concern warning, is substantially weaker than established industry leaders like Roche, Regeneron, and Novartis, which have robust revenue streams from approved products.
• Kodiak's clinical development timelines, with BLA filing for tarcocimab targeted for 2026, are typical for late-stage biopharmaceutical companies, but the prior failures of GLEAM and GLIMMER studies for tarcocimab contrast with the consistent success seen in pivotal trials for market-leading drugs like Regeneron's Eylea or Roche's Vabysmo.
• The company's reliance on its proprietary ABC Platform and bispecific therapies (KSI-501, KSI-101) represents an innovative approach to retinal diseases, aiming for differentiated efficacy and extended durability, which could offer a competitive advantage over existing single-mechanism anti-VEGF therapies if successful.
• Kodiak's dedicated manufacturing facility with Lonza (Ursus Facility) provides a level of control over supply chain that smaller biotechs often lack, potentially positioning it more favorably for commercial launch compared to peers entirely reliant on external CMOs, assuming the facility can be fully utilized and cost-effectively scaled.

Legal Proceedings

• Management is not aware of any matters that could have a material adverse effect on its financial position, results of operations or cash flows as of the date of this report.

Related Party Transactions

• The company has a liability related to the sale of future royalties to Baker Bros. Advisors, LP (BBA) amounting to $100 million as of June 30, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises and the risk of substantial losses due to the company's going concern doubt and increasing net losses. The stock price is highly volatile.
• **Employees:** The company's financial instability and need for cost reduction could impact job security, although the company is focused on attracting and retaining qualified personnel.
• **Customers (future):** If product candidates are approved, potential customers (patients and healthcare providers) could benefit from new treatment options for retinal diseases, especially if they offer differentiated efficacy or durability.
• **Suppliers/Creditors:** Face increased risk due to the company's financial condition and reliance on additional financing. The company relies on third-party manufacturers and suppliers for critical materials.
• **Regulatory Authorities:** The company's ongoing clinical trials and planned BLA submission will continue to engage regulatory bodies like the FDA and EMA, requiring strict compliance.

Next Steps

• Announce topline data for the primary endpoint for the GLOW2 study in Q1 2026.
• Announce topline data for the primary endpoint for the DAYBREAK study (tarcocimab and KSI-501) in Q3 2026.
• File a single Biologics License Application (BLA) for tarcocimab in wet AMD, DR, and RVO in 2026, after DAYBREAK topline data.
• Continue active enrollment for Phase 3 DAYBREAK study (tarcocimab and KSI-501) and Phase 3 PEAK and PINNACLE studies (KSI-101).
• Progress dual cytokine-targeting bispecific antibody programs (KSI-102, KSI-103) through pre-IND activities.
• Advance retina duet programs in glaucoma and geographic atrophy built with the ABC platform towards IND.
• Continue to monitor and reduce certain expenditures.
• Raise additional capital through equity or debt financings, collaborations, or similar transactions.

Key Dates

Recommendation

The company explicitly states 'substantial doubt regarding the Company's ability to continue as a going concern' and that its current cash 'may not be sufficient to meet the anticipated operating and capital expenditure requirements for the 12 months following the date of this Quarterly Report on Form 10-Q.' This severe liquidity issue, coupled with increasing net losses and no product revenue, presents an extremely high financial risk. While clinical programs are progressing, the fundamental financial viability is in question, making it a high-risk investment. A seasoned investor would likely prioritize capital preservation and avoid a company with such a significant going concern warning, regardless of pipeline potential.

Keywords

Retinal diseases, Biopharmaceutical, Clinical stage, Tarcocimab, KSI-501, KSI-101, Anti-VEGF, ABC Platform, Wet AMD, Diabetic retinopathy, Retinal vein occlusion, Macular edema, Ocular inflammation, Drug development, SEC filing, 10-Q, Biologics License Application, BLA, Going concern, Clinical trials, Biotechnology, Ophthalmology